Contact
searchSearch
HMP Global
Login

Support Resources

News
Patients Often Favor Receiving Information About Cancer Therapy From the Oncologist
02/14/2023
Yvette C. Terrie, BS Pharm, RPh
According to findings from a patient-completed questionnaire published in the Journal of Cancer Education, among oncology patients, many favored receiving pertinent information directly from the oncologist regarding various facets of...
According to findings from a patient-completed questionnaire published in the Journal of Cancer Education, among oncology patients, many favored receiving pertinent information directly from the oncologist regarding various facets of...
According to findings from a...
02/14/2023
Journal of Clinical Pathways
Research Reports
Post–COVID-19 Syndrome Clinical Pathway for the US Veterans Health Administration
02/06/2023
Allison M. Gustavson, DPT, PhD; Johnson Vachachira, NP; Claudia L. Campos, MD; Jacob B. Lindheimer, PhD; Kristina Crothers, MD; Omar Awan, MD; Carrie B. May, PsyD; Cristina Nguyen, BS; Courtney Sedillo, MSN, FNP-C; Francis J. Miller, Jr., MD
Lindheimer et al summarize the stepwise diagnostic approach for patients presenting with PCS dyspnea and/or cough in primary care and highlight teleconsultation and telerehabilitation as opportunities to reach those in rural areas or with...
Lindheimer et al summarize the stepwise diagnostic approach for patients presenting with PCS dyspnea and/or cough in primary care and highlight teleconsultation and telerehabilitation as opportunities to reach those in rural areas or with...
Lindheimer et al summarize the...
02/06/2023
Journal of Clinical Pathways
Trending From ACCC
Improving the Care of Patients With Advanced Nonmelanoma Skin Cancers
02/06/2023
In 2022, the Association of Community Cancer Centers (ACCC) developed the Advanced Non-Melanoma Skin Cancers Visiting Experts Program to educate multidisciplinary providers through interactive, virtual discussions on effective practices for...
In 2022, the Association of Community Cancer Centers (ACCC) developed the Advanced Non-Melanoma Skin Cancers Visiting Experts Program to educate multidisciplinary providers through interactive, virtual discussions on effective practices for...
In 2022, the Association of...
02/06/2023
Journal of Clinical Pathways
Debra Patt, MD, MPH, MBA
Videos
Reducing Disparities Through the Implementation of Digital Health Solutions in the Community Oncology Practice Setting
08/12/2022
Debra Patt, MD, MPH, MBA, implemented digital health solutions across a large practice, aiming to better understand which patient populations use these tools over time and characterize engagement across populations to enhance clinical...
Debra Patt, MD, MPH, MBA, implemented digital health solutions across a large practice, aiming to better understand which patient populations use these tools over time and characterize engagement across populations to enhance clinical...
Debra Patt, MD, MPH, MBA,...
08/12/2022
Journal of Clinical Pathways
Research Reports
Quality Measure Concepts to Fill Gaps in Assessing Oral Oncolytic Adherence: A Multistakeholder Measurement Strategy
06/16/2022
Sandra Kurtin, PhD; Leigh Boehmer, PharmD; Michael Reff, RPh, MBA; Rachael Peroutky, MSPH; David Blaisdell, BA; Shelley Fuld Nasso, MPP; Katie Schultz, MSPH; Tom Valuck, MD, JD
A multistakeholder workgroup of oncology and quality measurement experts explored gaps in quality measures focused on oral oncolytic adherence and identified, prioritized, and refined measure concepts for further development.
A multistakeholder workgroup of oncology and quality measurement experts explored gaps in quality measures focused on oral oncolytic adherence and identified, prioritized, and refined measure concepts for further development.
A multistakeholder workgroup of...
06/16/2022
Journal of Clinical Pathways
Conference Coverage
Real-World Utilization and Comparative Effectiveness of Treatment Options for Cancer–Associated Venous Thromboembolism
06/04/2022
Janelle Bradley
In the real-world setting, patients with cancer–associated venous thromboembolism remain on anticoagulation for a short period of time and DOACs and warfarin may be associated with better compliance than low molecular weight heparin.
In the real-world setting, patients with cancer–associated venous thromboembolism remain on anticoagulation for a short period of time and DOACs and warfarin may be associated with better compliance than low molecular weight heparin.
In the real-world setting,...
06/04/2022
Journal of Clinical Pathways
News
Immune Checkpoint Inhibitors May Have Been Used Inappropriately in Half of Study Patients with Advanced Cancer Who Were Near the End of Life
05/18/2022
Ellen Kurek
Immune checkpoint inhibitors (ICIs) have been shown to extend progression-free survival and overall survival in patients with a variety of cancers, leading to increases in the systemic treatment of patients with advanced cancer who are near...
Immune checkpoint inhibitors (ICIs) have been shown to extend progression-free survival and overall survival in patients with a variety of cancers, leading to increases in the systemic treatment of patients with advanced cancer who are near...
Immune checkpoint inhibitors...
05/18/2022
Journal of Clinical Pathways
Rachael Peroutky, MSPH
Quality Outlook
Nurses are Burned Out. Can Quality Measures Help?
04/11/2022
Sarena Ho, MSPH; Sara Khan Shirsekar; Katie Schultz, MSPH; Rachael Peroutky, MSPH; Tom Valuck, MD, JD; Elizabeth Donckels, MSPH
This blog addresses "nurse burnout," the occupational phenomena that many nurses face, and suggests that quality measurement strategies for nurse burnout may be most effective in the hospital setting since evidence tying burnout to patient...
This blog addresses "nurse burnout," the occupational phenomena that many nurses face, and suggests that quality measurement strategies for nurse burnout may be most effective in the hospital setting since evidence tying burnout to patient...
This blog addresses "nurse...
04/11/2022
Journal of Clinical Pathways
Research Reports
Factors Associated With Poor Outcomes in Patients who Receive Cancer Directed Therapy at the End of Life
02/15/2022
Megan Wall, MS; Ila M. Saunders, PharmD, BCOP; Janine Martino, PharmD, BCOP, APh; Alison Wall, MS; Shanna Block, PharmD, BCOP; Rabia S. Atayee, PharmD, BCPS; Katherine Medley, PharmD; Yasmine Anouty, PharmD; Carolyn Mulroney, MD
Yasmine Anouty, PharmD, and colleagues discern factors that may be associated with poor outcomes in adult patients who received intravenous cancer-directed therapy in the last 30 days of life.
Yasmine Anouty, PharmD, and colleagues discern factors that may be associated with poor outcomes in adult patients who received intravenous cancer-directed therapy in the last 30 days of life.
Yasmine Anouty, PharmD, and...
02/15/2022
Journal of Clinical Pathways

Expert Insights

Debra Patt, MD, MPH, MBA
Videos
Reducing Disparities Through the Implementation of Digital Health Solutions in the Community Oncology Practice Setting
08/12/2022
Debra Patt, MD, MPH, MBA, implemented digital health solutions across a large practice, aiming to better understand which patient populations use these tools over time and characterize engagement across populations to enhance clinical...
Debra Patt, MD, MPH, MBA, implemented digital health solutions across a large practice, aiming to better understand which patient populations use these tools over time and characterize engagement across populations to enhance clinical...
Debra Patt, MD, MPH, MBA,...
08/12/2022
Journal of Clinical Pathways
Interview
Building Clinical Pathways With an Emphasis on Specific Community Needs
12/16/2020
Carla Baker, RN, discusses the Memphis Breast Cancer Consortium, including the organization's mission, structure, and approach to pathways design.
Carla Baker, RN, discusses the Memphis Breast Cancer Consortium, including the organization's mission, structure, and approach to pathways design.
Carla Baker, RN, discusses the...
12/16/2020
Journal of Clinical Pathways
Healthcare Economist
PCORI to Incorporate Cost But Not Cost-Effectiveness in its New Principles
10/09/2020
Jason Shafrin, PhD, highlights the Patient-Centered Outcomes Research Institute's (PCORI) Proposed “Principles” for the Consideration of the Full Range of Outcomes Data.
Jason Shafrin, PhD, highlights the Patient-Centered Outcomes Research Institute's (PCORI) Proposed “Principles” for the Consideration of the Full Range of Outcomes Data.
Jason Shafrin, PhD, highlights...
10/09/2020
Journal of Clinical Pathways
Guest Blog
Achieving “Victory” Through Holistic Palliative Care
07/03/2019
Adil Akhtar, MD
Adil Akhtar, MD, offers the perspective that, if patients can learn to see their bodies as more important than their cancer, they will be more likely to agree to and continue palliative care.
Adil Akhtar, MD, offers the perspective that, if patients can learn to see their bodies as more important than their cancer, they will be more likely to agree to and continue palliative care.
Adil Akhtar, MD, offers the...
07/03/2019
Journal of Clinical Pathways
Guest Blog
Pharmacogenomics: Preemptive Testing Decisions Reach Across the Care Team
01/07/2019
Kandace Schuft, PharmD
Kandace Schuft, PharmD, discusses the challenges of implementing pharmacogenomics testing in actual practice and determining its place in the workflow of multiple care teams.
Kandace Schuft, PharmD, discusses the challenges of implementing pharmacogenomics testing in actual practice and determining its place in the workflow of multiple care teams.
Kandace Schuft, PharmD,...
01/07/2019
Journal of Clinical Pathways
Guest Blog
Why Palliative Care is More Than Just Care for the Dying
04/28/2018
Tim Holder, MD
Many physicians still mistakenly believe that hospice and palliative medicine are one and the same, according to Timothy W Holder, MD, medical director, supportive care and survivorship, Cancer Treatment Centers of America.
Many physicians still mistakenly believe that hospice and palliative medicine are one and the same, according to Timothy W Holder, MD, medical director, supportive care and survivorship, Cancer Treatment Centers of America.
Many physicians still mistakenly...
04/28/2018
Journal of Clinical Pathways
Headshot of Dr Basu Roy
Interview
Improving Therapy Options and Patient Experiences in NSCLC: Part 1
10/13/2026
Upal Basu Roy, PhD, MPH
In this interview, Upal Basu Roy, PhD, MPH, discusses improvements in the treatment landscape of non–small cell lung cancer (NSCLC) as well as ongoing research aimed at further enhancing disease management.
In this interview, Upal Basu Roy, PhD, MPH, discusses improvements in the treatment landscape of non–small cell lung cancer (NSCLC) as well as ongoing research aimed at further enhancing disease management.
In this interview, Upal Basu...
10/13/2026
Journal of Clinical Pathways
Gary Simmons, DO, MSHA
Interview
Expanding CAR T-Cell Therapy Access in Community Oncology
09/29/2026
Gary L. Simmons, DO
Gary L. Simmons, DO, MSHA, discusses Virginia Oncology Associates’ experience delivering CAR T-cell therapy in the community and how community-based programs can expand patient access while supporting safe delivery, care coordination, and...
Gary L. Simmons, DO, MSHA, discusses Virginia Oncology Associates’ experience delivering CAR T-cell therapy in the community and how community-based programs can expand patient access while supporting safe delivery, care coordination, and...
Gary L. Simmons, DO, MSHA,...
09/29/2026
Journal of Clinical Pathways
Nikki Martin Headshot
Interview
Adopting Reflex Biomarker Testing to Improve Clinical Workflows for Patients With Non–Small Cell Lung Cancer
09/18/2026
Nikki Martin, MA
In this interview, Nikki Martin, MA, discusses the benefits of comprehensive biomarker testing for patients with newly diagnosed non–small cell lung cancer (NSCLC), explaining how it can streamline decision-making processes, improve clinical...
In this interview, Nikki Martin, MA, discusses the benefits of comprehensive biomarker testing for patients with newly diagnosed non–small cell lung cancer (NSCLC), explaining how it can streamline decision-making processes, improve clinical...
In this interview, Nikki Martin,...
09/18/2026
Journal of Clinical Pathways
Kelsey Pan Headshot
Interview
Navigating Biomarker-Driven Treatment in Advanced NSCLC: Part II
08/18/2026
Kelsey Pan, MD
A guest expert discusses evolving approaches to managing treatment resistance in non-small cell lung cancer, barriers to equitable precision oncology, and emerging targeted therapies that may shape future treatment strategies.
A guest expert discusses evolving approaches to managing treatment resistance in non-small cell lung cancer, barriers to equitable precision oncology, and emerging targeted therapies that may shape future treatment strategies.
A guest expert discusses...
08/18/2026
Journal of Clinical Pathways
Kelsey Pan Headshot
Interview
Navigating Biomarker-Driven Treatment in Advanced NSCLC: Part I
08/18/2026
Kelsey Pan, MD
In this interview, Kelsey Pan, MD, MPH, discusses how biomarker testing and emerging targeted therapies are reshaping treatment selection, resistance management, and precision oncology in advanced non–small cell lung cancer (NSCLC).
In this interview, Kelsey Pan, MD, MPH, discusses how biomarker testing and emerging targeted therapies are reshaping treatment selection, resistance management, and precision oncology in advanced non–small cell lung cancer (NSCLC).
In this interview, Kelsey Pan,...
08/18/2026
Journal of Clinical Pathways
Deirdre Saulet, PhD
Blog
How AI, Data, and Real-World Evidence Are Transforming Oncology Clinical Pathways
07/14/2026
Deirdre Saulet, PhD
Clinical Pathways Congress 2026 will bring together oncology leaders to explore practical strategies for using technology to build smarter, more responsive clinical pathways that improve care delivery.
Clinical Pathways Congress 2026 will bring together oncology leaders to explore practical strategies for using technology to build smarter, more responsive clinical pathways that improve care delivery.
Clinical Pathways Congress 2026...
07/14/2026
Journal of Clinical Pathways
B-cell lymphoma
Videos
Dual-Targeting CAR T-Cell Therapy: Implications for Relapsed or Refractory Large B-Cell Lymphoma
07/06/2026
Paolo Strati, MD
Paolo Strati, MD, discusses how findings from the ZUMA-14 trial could shape the future of dual-targeting CAR T-cell therapy, treatment sequencing, and minimal residual disease monitoring in relapsed or refractory large B-cell lymphoma.
Paolo Strati, MD, discusses how findings from the ZUMA-14 trial could shape the future of dual-targeting CAR T-cell therapy, treatment sequencing, and minimal residual disease monitoring in relapsed or refractory large B-cell lymphoma.
Paolo Strati, MD, discusses how...
07/06/2026
Journal of Clinical Pathways
Non-small cell lung cancer, NSCLC
Videos
Evaluating First-Line TKIs in ALK-Positive NSCLC: Insights From a Large Real-World Analysis: Part 2
06/19/2026
Rahul Mudumba, PhD, MHS
Dr Rahul Mudumba discusses how emerging real-world evidence may help differentiate ALK-targeted therapies for non–small cell lung cancer (NSCLC), highlighting the promise of lorlatinib, the importance of patient-specific treatment decisions,...
Dr Rahul Mudumba discusses how emerging real-world evidence may help differentiate ALK-targeted therapies for non–small cell lung cancer (NSCLC), highlighting the promise of lorlatinib, the importance of patient-specific treatment decisions,...
Dr Rahul Mudumba discusses how...
06/19/2026
Journal of Clinical Pathways
NSCLC, non-small cell lung cancer
Videos
Evaluating First-Line TKIs in ALK-Positive NSCLC: Insights From a Large Real-World Analysis
06/18/2026
Rahul Mudumba, PhD, MHS
Rahul Mudumba, PhD, explains how real-world evidence is helping clarify first-line treatment selection among ALK-targeted therapies in ALK-positive non–small cell lung cancer (NSCLC).
Rahul Mudumba, PhD, explains how real-world evidence is helping clarify first-line treatment selection among ALK-targeted therapies in ALK-positive non–small cell lung cancer (NSCLC).
Rahul Mudumba, PhD, explains how...
06/18/2026
Journal of Clinical Pathways
Specialty Pharmacy, Clinical Pathways, Oncology
Videos
Building Better Oncology Pathways With Specialty Pharmacy Integration: Part 2
06/17/2026
Kishen Patel, PharmD
Kishen Patel, PharmD, explores how integrated specialty pharmacy services are helping health systems reduce acute care utilization, strengthen oncology pathways, and demonstrate the long-term value of pharmacist-led care.
Kishen Patel, PharmD, explores how integrated specialty pharmacy services are helping health systems reduce acute care utilization, strengthen oncology pathways, and demonstrate the long-term value of pharmacist-led care.
Kishen Patel, PharmD, explores...
06/17/2026
Journal of Clinical Pathways

Newsfeed

News
Patients Often Favor Receiving Information About Cancer Therapy From the Oncologist
02/14/2023
Yvette C. Terrie, BS Pharm, RPh
According to findings from a patient-completed questionnaire published in the Journal of Cancer Education, among oncology patients, many favored receiving pertinent information directly from the oncologist regarding various facets of...
According to findings from a patient-completed questionnaire published in the Journal of Cancer Education, among oncology patients, many favored receiving pertinent information directly from the oncologist regarding various facets of...
According to findings from a...
02/14/2023
Journal of Clinical Pathways
Conference Coverage
Real-World Utilization and Comparative Effectiveness of Treatment Options for Cancer–Associated Venous Thromboembolism
06/04/2022
Janelle Bradley
In the real-world setting, patients with cancer–associated venous thromboembolism remain on anticoagulation for a short period of time and DOACs and warfarin may be associated with better compliance than low molecular weight heparin.
In the real-world setting, patients with cancer–associated venous thromboembolism remain on anticoagulation for a short period of time and DOACs and warfarin may be associated with better compliance than low molecular weight heparin.
In the real-world setting,...
06/04/2022
Journal of Clinical Pathways
News
Immune Checkpoint Inhibitors May Have Been Used Inappropriately in Half of Study Patients with Advanced Cancer Who Were Near the End of Life
05/18/2022
Ellen Kurek
Immune checkpoint inhibitors (ICIs) have been shown to extend progression-free survival and overall survival in patients with a variety of cancers, leading to increases in the systemic treatment of patients with advanced cancer who are near...
Immune checkpoint inhibitors (ICIs) have been shown to extend progression-free survival and overall survival in patients with a variety of cancers, leading to increases in the systemic treatment of patients with advanced cancer who are near...
Immune checkpoint inhibitors...
05/18/2022
Journal of Clinical Pathways
News
Early Palliative Care Reduces End-of-Life Health Care Costs
09/14/2021
Among patients with cancer, receipt of early palliative care reduced the average health system costs in the last month of life, especially through avoided hospitalizations.
Among patients with cancer, receipt of early palliative care reduced the average health system costs in the last month of life, especially through avoided hospitalizations.
Among patients with cancer,...
09/14/2021
Journal of Clinical Pathways
News
Impact of Performance Status on Outcomes Among Patients Receiving ICIs for Advanced Tumors
09/03/2021
Findings from a recent study suggest avoiding the use immune checkpoint inhibitors in patients with advanced malignancy and poor performance status, as the outcomes are poor in this group.
Findings from a recent study suggest avoiding the use immune checkpoint inhibitors in patients with advanced malignancy and poor performance status, as the outcomes are poor in this group.
Findings from a recent study...
09/03/2021
Journal of Clinical Pathways
News
Understanding the Stigmatization of Palliative Care Referral in Oncology
08/24/2021
Findings from a recent study suggest strategies for oncology clinicians to reduce the stigmatizing association of palliative care with end of life.
Findings from a recent study suggest strategies for oncology clinicians to reduce the stigmatizing association of palliative care with end of life.
Findings from a recent study...
08/24/2021
Journal of Clinical Pathways
Conference Coverage
Integrating Palliative Care Into Community Oncology Practice
04/29/2021
04/29/2021
Journal of Clinical Pathways
News
Variation in Treatment Planning of Radiation Therapy Procedures in the United States
02/19/2021
02/19/2021
Journal of Clinical Pathways
News
Episode-Based Payment Model Shortens Radiotherapy Courses But Reduces Reimbursements
11/28/2020
The Radiation Oncology Alternative Payment Model encourages shorter courses of radiotherapy, but emerging technologies with large capital and operating investment needs may see reductions in reimbursements, according to a recent study.
The Radiation Oncology Alternative Payment Model encourages shorter courses of radiotherapy, but emerging technologies with large capital and operating investment needs may see reductions in reimbursements, according to a recent study.
The Radiation Oncology...
11/28/2020
Journal of Clinical Pathways
News
Insurance Restrictions and High Costs Limit Blood Cancer Treatment Access
10/14/2026
Grace Taylor, MS, MA
A nationwide study found that insurance restrictions and high out-of-pocket costs prevent many patients with blood cancers from filling prescribed oral anticancer medications, even after insurer approval.
A nationwide study found that insurance restrictions and high out-of-pocket costs prevent many patients with blood cancers from filling prescribed oral anticancer medications, even after insurer approval.
A nationwide study found that...
10/14/2026
Journal of Clinical Pathways
News
EOM Lung Patient Pilot Associated With Reduced Emergency Care Utilization
10/09/2026
Rebecca Amrick
In the Enhancing Oncology Model (EOM) Lung Patient Pilot program, nurse outreach was associated with reduced emergency care utilization and health care spending among patients with metastatic lung cancer.
In the Enhancing Oncology Model (EOM) Lung Patient Pilot program, nurse outreach was associated with reduced emergency care utilization and health care spending among patients with metastatic lung cancer.
In the Enhancing Oncology Model...
10/09/2026
Journal of Clinical Pathways
News
MYLUNG Study Links Timely Biomarker Testing to Improved Outcomes in mNSCLC
09/29/2026
Rebecca Amrick
Protocol 2 of the MYLUNG study found that improvements in biomarker testing rates increased rates of targeted first-line therapies among patients with metastatic non–small cell lung cancer (mNSCLC), illustrating how biomarker testing can...
Protocol 2 of the MYLUNG study found that improvements in biomarker testing rates increased rates of targeted first-line therapies among patients with metastatic non–small cell lung cancer (mNSCLC), illustrating how biomarker testing can...
Protocol 2 of the MYLUNG study...
09/29/2026
Journal of Clinical Pathways
News
Comprehensive Molecular Profiling Linked to Improved Survival in NSCLC
09/28/2026
Grace Taylor, MS, MA
A study found that comprehensive molecular profiling was associated with improved survival and reduced health care utilization among patients with non–small cell lung cancer (NSCLC), yet fewer than 1 in 15 patients underwent testing.
A study found that comprehensive molecular profiling was associated with improved survival and reduced health care utilization among patients with non–small cell lung cancer (NSCLC), yet fewer than 1 in 15 patients underwent testing.
A study found that comprehensive...
09/28/2026
Journal of Clinical Pathways
Conference Coverage
Innovations in Relapsed or Refractory Multiple Myeloma Management
09/21/2026
Rebecca Amrick
At the National Comprehensive Cancer Network 2026 Annual Congress: Hematologic Malignancies, panelists discussed innovations in treating relapsed or refractory multiple myeloma and strategies to improve disease management.
At the National Comprehensive Cancer Network 2026 Annual Congress: Hematologic Malignancies, panelists discussed innovations in treating relapsed or refractory multiple myeloma and strategies to improve disease management.
At the National Comprehensive...
09/21/2026
Journal of Clinical Pathways
Conference Coverage
Managing Treatment Toxicity Among Patients With Chronic Myeloid Lymphoma
09/21/2026
Rebecca Amrick
Jenna Moran, MSN, FNP-BC, outlined strategies for managing tyrosine kinase inhibitor–related toxicities in patients with chronic myeloid leukemia during a session at the National Comprehensive Cancer Network 2026 Annual Congress.
Jenna Moran, MSN, FNP-BC, outlined strategies for managing tyrosine kinase inhibitor–related toxicities in patients with chronic myeloid leukemia during a session at the National Comprehensive Cancer Network 2026 Annual Congress.
Jenna Moran, MSN, FNP-BC,...
09/21/2026
Journal of Clinical Pathways
Conference Coverage
De-Escalating TKI Therapy Based on Risk and Response for Patients With CML
09/18/2026
Rebecca Amrick
At the National Comprehensive Cancer Network 2026 Annual Congress: Hematologic Malignancies, Vivian G. Oehler, MD, shared insights on de-escalating tyrosine kinase inhibitor (TKI) therapy among patients with chronic myeloid leukemia (CML)...
At the National Comprehensive Cancer Network 2026 Annual Congress: Hematologic Malignancies, Vivian G. Oehler, MD, shared insights on de-escalating tyrosine kinase inhibitor (TKI) therapy among patients with chronic myeloid leukemia (CML)...
At the National Comprehensive...
09/18/2026
Journal of Clinical Pathways
News
Anemia Associated With Higher Mortality and AML Transformation Risk in Myelofibrosis
09/17/2026
Rebecca Amrick
Researchers found that the presence of anemia is likely to increase the risk of mortality and acute myeloid leukemia (AML) transformation among patients with myelofibrosis, indicating anemia as a potential prognostic marker.
Researchers found that the presence of anemia is likely to increase the risk of mortality and acute myeloid leukemia (AML) transformation among patients with myelofibrosis, indicating anemia as a potential prognostic marker.
Researchers found that the...
09/17/2026
Journal of Clinical Pathways
News
Enhanced Financial Assistance Associated With Improved Radiotherapy Completion
09/08/2026
Rebecca Amrick
Researchers found that providing financial assistance for cancer patients with unmet social needs was associated with improvements in radiotherapy completion, indicating a potential strategy to promote health equity and reduce care gaps.
Researchers found that providing financial assistance for cancer patients with unmet social needs was associated with improvements in radiotherapy completion, indicating a potential strategy to promote health equity and reduce care gaps.
Researchers found that providing...
09/08/2026
Journal of Clinical Pathways
News
Molecular Testing Improves Survival Outcomes for Patients With Endometrial Cancer, Study Finds
09/03/2026
Rebecca Amrick
Researchers found that testing for molecular biomarkers in patients with endometrial cancer is associated with prolonged survival and lower incremental costs than no testing, illustrating the importance of molecular classification in...
Researchers found that testing for molecular biomarkers in patients with endometrial cancer is associated with prolonged survival and lower incremental costs than no testing, illustrating the importance of molecular classification in...
Researchers found that testing...
09/03/2026
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Why is There Variation in Treatment Planning for Medicare Patients?
04/06/2021
04/06/2021
Journal of Clinical Pathways
Quiz
Regional Inequalities Persist in Lung Cancer Mortality Trends
11/19/2025
11/19/2025
Journal of Clinical Pathways
Quiz
Rural Health Transformation Program Fund Distribution
09/29/2025
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health...
09/29/2025
Journal of Clinical Pathways
Quiz
Uncovering the True Cost of Care
09/18/2025
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable...
09/18/2025
Journal of Clinical Pathways
Quiz
Understanding the NCCN Guidelines Navigator
08/27/2025
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive...
08/27/2025
Journal of Clinical Pathways
Quiz
Specialty Palliative Care Trends for Medicare Beneficiaries
08/12/2025
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of...
08/12/2025
Journal of Clinical Pathways
Quiz
Understanding the Role of Clinical Pathways in Oncology Care
07/30/2025
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical...
07/30/2025
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways

Special Reports

Special Report
Advancing a Standardized Economic Framework to Power Oncology Pathways: Methods and Model Development From Phase II of the Predictable Cost of Care Working Group
04/23/2026
Edward Arrowsmith, MD; Alan J. Balch, PhD, MSc; Vishnukamal Golla, MD, MPH; Andrew Hertler, MD, FACP; David Jackman, MD; Olaf Lodbrok, MS, MBA; Lalan Wilfong, MD; Gordon Kuntz; Carole Tremonti, RN, MBA
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and...
04/23/2026
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use